Avrobio reports positive data from Phase I/II cystinosis gene therapy trial
The trial is assessing the safety and efficacy of AVR-RD-04 in adults with the infantile form of cystinosis.
Healthcare
Latest in
Healthcare
Complete responses reported for Nkarta’s off-the-shelf NK cell therapies
On April 25, Nkarta, a biopharmaceutical company developing off-the-shelf engineered natural killer (NK) cell therapies, announced highly promising results from…
By
A CRL and other hurdles ahead for Axsome Therapeutics’s migraine treatment, AXS-07
On April 25, Axsome Therapeutics revealed that chemistry, manufacturing and controls (CMS) issues were identified during the US Food and…
By
Meningitis vaccination may offer cross-protection against gonorrhoea infection
Gonorrhoea is the second most common nationally notifiable sexually transmitted infection (STI) in the US. It affects both men and…
By
Overcoming vaccine scepticism in Africa will reduce malaria burden
Malaria is a vector-borne disease caused by parasites of the genus Plasmodium. Malaria is transmitted through the bite of the…
By
Covid-19 diagnoses may drive increase in heart failure cases
As the Covid-19 pandemic stretches into its third year, the long-term effects of acute infection are beginning to become more…
By
Risk of major depression increases by 60% in patients with atopic dermatitis
Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognised as a mood disorder that…
By
FDA grants approval for BioCardia’s Covid-19 stem cell therapy trial
The initial portion of the trial will assess increasing doses of the NK1R+ MSCs in adult patients.